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Abstract: RNA sequencing (RNAseq) can be a powerful tool in the identification of transcriptional
changes after drug treatment. RNAseq was utilized to determine expression changes in Fluorescence-
activated cell sorted (FACS) CD11b/c+ cells from the striatum (STR) and prefrontal cortex (PFC)
of male Sprague-Dawley rats after a methamphetamine (METH) binge dosing regimen. Resident
microglia and infiltrating macrophages were collected 2 h or 3 days after drug administration.
Gene expression changes indicated there was an increase toward an overall pro-inflammatory state,
or M1 polarization, along with what appears to be a subset of cells that differentiated toward the
anti-inflammatory M2 polarization. In general, there were significantly more mRNA expression
changes in the STR than the PFC and more at 2 h post-binge METH than at 3 days post-binge METH.
Additionally, Ingenuity® Pathway Analysis along with details of RNA expression changes revealed
cyclo-oxygenase 2 (COX2)-driven prostaglandin (PG) E2 synthesis, glutamine uptake, and the Nuclear
factor erythroid2-related factor 2 (NRF2) canonical pathway in microglia were associated with the
binge administration regimen of METH.
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1. Introduction
Methamphetamine (METH) is known to induce neuroinflammation. Resident glial cells, including
microglia [1–3] and astrocytes [4–6] in the brain are implicated in contributing to this METH-induced
neuroinflammation via production and release of a variety of inflammatory mediators, such as
interleukin (IL) 1β [7,8], IL6 [9,10], tumor necrosis factor (TNF) α [11], C-C motif chemokine ligand 2
(CCL2) [12], reactive oxygen species (ROS) [13,14], and nitric oxide [15]. Inducible enzymes that can
lead to the production of additional inflammatory mediators in these glial cells, such as COX2 [16,17],
have also been implicated. However, the specific cellular origin of these pro-inflammatory mediators
has yet to be defined.
The canonical role of central nervous system (CNS)-resident microglia is to serve as sentinels to
detect disturbances in the chemical environment around neurons and to respond to these disturbances.
In their response to locally detected lipopolysaccharide (LPS) or interferon-gamma (INF-γ), microglia
can take on the role known as the M1 phenotype. As an activated M1 microglia, the microglia produce
and release pro-inflammatory mediators. In contrast, microglia can take on an M2 phenotype if
stimulated locally by IL4 or IL13. In this state of activation, the microglial cell produces and releases
mediators such as IL10, which can serve as an anti-inflammatory signal to initiate recovery from
an insult.
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The current study focused on the role of microglia at 2 h and 3 days after administration of
neurotoxic binge doses of METH to evaluate time-dependent, acute, and persistent changes in gene
transcription within microglia and infiltrating macrophages. We evaluated changes in gene transcription
in the rat striatum (STR) and prefrontal cortex (PFC), areas associated with controlling voluntary
movement, reward, motivation, and executive functions such as planning and decision-making [18–21],
all of which are affected by METH [22–25].
2. Materials and Methods
2.1. Animals
All experiments were conducted with approval of the Institutional Animal Care and Use Committee
at the Indiana University School of Medicine and performed in American Association for Laboratory
Animal Care (AALAC)-approved facilities. Male Sprague-Dawley rats were purchased from Envigo
(Indianapolis, IN, USA) and received food and water ad libitum. After a period of acclimation, the rats
were randomly divided into either control (saline) or treated (METH) groups. Methamphetamine
(METH) HCl was from Sigma-Aldrich (St. Louis, MO, USA, Catalog #M-8750). A 10 mg/mL METH
solution was prepared the day of injections in sterile-filtered 0.9% w/v sodium chloride (saline).
Rats received intraperitoneal (i.p.) injections of either saline or 10 mg/mL METH at a volume equal to
1 mL/kg (10 mg METH/kg body mass). Injections were given at 2 h intervals over 8 h for a total of
4 injections. Rats were housed individually during the injections in plastic shoebox-style containers
with a wire lid. Food and water were available ad libitum. A plastic grate was placed on top of
the bedding inside the container to prevent aspiration of bedding material. Body temperature was
monitored at 15–30 min intervals throughout the injection period and for 1–2 h after the final injection
via a subcutaneously-implanted temperature transponder (Bio Medic Data Systems, Inc., Seaford, DE,
USA, Catalog # IPTT 300). If a rat’s body temperature exceeded 40 ◦C, measures were taken (oscillating
fan, ice packs on cage lid) to prevent hyperthermia. At either 2 h or 3 days after the last i.p. injection,
each rat was deeply anesthetized with an i.p. injection of a ketamine (Henry Schein, Indianapolis,
IN USA, KetathesiaTM 100 mg/mL)/xylazine (Akorn Pharmaceuticals, Decatur, IL, USA, AnaSed®
Injection 20 mg/mL) 70%/30% v/v mix. Once a rat had no response to a toe-pinch, the chest cavity was
opened and 0.35 mL heparin (Sagent Pharmaceuticals, Inc, Schaumburg, IL, USA, 1000 USP units/mL)
was injected into the left ventricle, followed by perfusion with ice-cold phosphate-buffered saline (PBS).
Blood and PBS exited the body through an incision made in the right atrium. Perfusion continued for
5 min at a flow rate of 20 mL/min. We chose to perfuse with PBS prior to brain extraction to reduce the
contribution of circulating macrophages contained within the brain’s capillaries, thereby restricting
our collection to Cd11b/c+ cells that reside within the brain parenchyma.
The rat was decapitated via guillotine and the whole brain was removed from the skull. The brain
was bisected on ice into its right and left hemispheres via RNase Away®-treated (Thermo Fisher,
Waltham, MA, USA, #7005-11) razor blade and the striatum and prefrontal cortex were blunt-dissected
from each hemisphere. The two pieces of the same region were combined into a single DNase-free
RNase-free 1.5 mL tube containing 200 µL of ice cold dissociation buffer (see below).
The number of rats per group were: 2 h post saline STR (6), 2 h post METH STR (8), 2 h post saline
PFC (4), 2 h post METH (5). The respective numbers for the 3 day groups were 6, 7, 6, and 7.
2.2. Buffers and Antibodies for Single-Cell Suspensions
For the mechanical dissociation of STR and PFC to a single-cell suspension, several buffers
were prepared. Diethyl pyrocarbonate (DEPC)-phosphate-buffered saline (PBS) pH 7.4 was prepared
using DEPC-treated water (Thermo Fisher, AM9922) containing 150 mM sodium chloride (Santa
Cruz Biotechnology, Dallas, TX, sc-203274B), 1.5 mM sodium phosphate monobasic (Sigma-Aldrich
S-9638), and 17.5 mM sodium phosphate dibasic (Thermo Fisher, S374-1). Dissociation buffer was
prepared with DEPC-PBS supplemented with RNase-free DNase (Qiagen, Hilden, Germany) 79254,
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stock = 2.72 units/µL, final concentration in DEPC-PBS = 40 units/mL) and RNasin® Plus RNase
Inhibitor (Promega, Madison, WI, USA, N2615, stock = 40 units/µL, final concentration in DEPC-PBS
= 80 units/mL). Blocking buffer consisted of DEPC-PBS with 1% w/v bovine serum albumin (BSA)
(Sigma-Aldrich, A3059), 80 units/mL RNasin® Plus RNase Inhibitor and 5% v/v normal mouse serum
(Sigma-Aldrich, M5905). Blocked cells were divided, with a fraction of the cells incubated with
phycoerythrin (PE)-labeled isotype IgG2a control antibody (Abcam, Cambridge, MA, USA, ab91363)
and the remainder of the cells incubated with mouse monoclonal phycoerythrin (PE)-labeled antibody
to CD11b/c (Abcam, ab112239) in blocking buffer. For fluorescence activated cell sorting (FACS),
stained and washed cells were resuspended in DEPC-PBS with 1% w/v BSA and 80 units/mL RNasin®
Plus RNase Inhibitor (Promega).
2.3. Mechanical Dissociation
Keeping the tissue-containing tube on ice, an RNase Away®-treated plastic pestle designed to
fit a 1.5 mL tube was used to gently disrupt the tissue to smaller pieces. Another 300 µL ice cold
dissociation buffer was added to a final volume of 500 µL. Any remaining tissue chunks were mashed.
The suspension was filtered through 100 micron mesh into a clean 1.5 mL DNase-free, RNase-free tube
on ice. The filter was washed with another 500 µL dissociation buffer into the same tube. The combined
filtrate was centrifuged 5 min 2500× g at 4 ◦C to pellet the cells. After aspirating the supernatant,
the cells were blocked and incubated with PE-labeled CD11b/c+ antibody.
2.4. Blocking and Staining Rat Striatal Cells
One mL of blocking buffer was added to each cell pellet and the cells were resuspended by gentle
pipetting. The tubes were closed and rocked for 10 min at room temperature (RT). Fifty µL was removed
from each sample and combined in a common tube for gating of cells via flow cytometry (FACS).
Another 50 µL was removed from each sample to combine into a negative control for PE nonspecific
binding with the PE-labeled isotype control antibody. The remaining 900 µL of cells from each sample
were used for PE-labeled CD11b/c antibody labeling. All tubes were spun for 5 min at 2500× g 4 ◦C
to pellet the cells. Supernatant was discarded. Cell pellets from each sample to be incubated with
PE-labeled CD11b/c antibody were resuspended in 500 µL of blocking buffer containing 5 µL (0.5 µg)
of antibody. A proportionate amount of PE-labeled isotype control antibody was incubated with
the resuspended cell pellet for nonspecific PE binding. The resuspended cell pellet that would not
receive any antibody was incubated in the same volume of blocking buffer as the isotype control pellet.
All tubes were wrapped in foil to protect the fluorescent label from light and rotated end-over-end
overnight at 4 ◦C.
2.5. FACS and RNA Isolation
The next morning, the cells were collected by centrifuging the tubes for 5 min at 2500× g 4 ◦C. After
aspirating the supernatant, each cell pellet was washed twice by resuspending it in 500 µL DEPC-PBS,
centrifuging, and aspirating the DEPC-PBS. The final pellet was resuspended in DEPC-PBS + 1% BSA
+ RNasin® Plus RNase Inhibitor for cell sorting on BD Biosciences FACSAria flow cytometers. Figure 1
is representative of the gating strategy used to isolate PE-CD11b/c+ cells (P3). The collected CD11b/c+
cells were pelleted by centrifugation at 16,000× g for 5 min at 4 ◦C. After aspirating the supernatant,
the pellet was resuspended in 50 µL Solution XB (ArcturusTM PicoPureTM RNA Isolation Kit, Thermo
Fisher, KIT0204) and incubated at 42 ◦C for 30 min. To remove any insoluble material, the tubes were
spun at 3000× g for 2 min and the cleared supernatant was transferred to a clean DNase-free RNase-free
1.5 mL tube. Total RNA was isolated as per the instructions provided with the ArcturusTM PicoPureTM
RNA Isolation Kit instructions (ThermoFischer), including optional on-column DNase treatment.
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Figure 1. Representative gating strategy to collect CD11b/c+ cells (P3) by FACS for RNA sequencing. 
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isolate Cd11b/c-PE labeled cells (P3). 
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USA). Each library was quantified and its quality accessed by Qubit and Agilent Bioanalyzer, and 
multiple libraries were pooled in equal molarity. The average size of the library insert was about 150–
200 b. Five microliters of 2 nM pooled libraries per lane were then denatured, neutralized, and 
applied to the cBot for flow cell deposition and cluster amplification, before loading on to HiSeq 4000 
for 75 b paired-end sequencing (Illumina, Inc.). Each lane generated approximately 300–350 million 
reads. A Phred quality score (Q score) was used to measure the quality of sequencing. More than 90% 
of the sequencing reads reached Q30 (99.9% base call accuracy). 
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The sequencing data were first assessed using FastQC (Babraham Bioinformatics, Cambridge, 
UK) for quality control. All sequenced libraries were mapped to the rat genome (mm10) using STAR 
RNA-seq aligner [26] with the following parameter: “--outSAMmapqUnique 60”. The reads 
distribution across the genome was assessed using bamutils (from ngsutils) [27]. Uniquely mapped 
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Ingenuity® Pathway Analysis (IPA®) software (Qiagen, Germantown, MD, USA) was employed 
to analyze relationships between genes that exhibited significant differential expression (FDR < 0.05) 
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2.6. Clontech SMART-Seq V4 Ultra Low Input RNA Methods for Illumina HiSeq 4000 Sequencing
Purified total RNA was first evaluated for its quantity and quality, using Agilent Bioanalyzer
2100 (Agilent, Santa Clara, CA, USA). One nanogram of total RNA per sample was used for library
preparation. cDNA was first synthesized using SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing
(Takara Clontech Laboratories, Inc., Mountain View, CA, USA). Dual indexed cDNA library was then
prepared using Nextera XT DNA Library Prep Kit (Illumina, Inc., San Diego, CA, USA). Each library
was quantified and its quality accessed by Qubit and Agilent Bioanalyzer, and multiple libraries were
pooled in equal molarity. The average size of the library insert was about 150–200 b. Five microliters of
2 nM pooled libraries per lane were then denatured, neutralized, and applied to the cBot for flow cell
deposition and cluster amplification, before loading on to HiSeq 4000 for 75 b paired-end sequencing
(Illumina, Inc.). Each lane generated approximately 300–350 million reads. A Phred quality score (Q
score) was used to measure the quality of sequencing. More than 90% of the sequencing reads reached
Q30 (99.9% base call accuracy).
2.7. Sequence Alignment and Gene Counts
The sequencing data were first assessed using FastQC (Babraham Bioinformatics, Cambridge,
UK) for quality control. All sequenced libraries were mapped to the rat genome (mm10) using
STAR RNA-seq aligner [26] with the following parameter: “–outSAMmapqUnique 60”. The reads
distribution across the genome was assessed using bamutils (from ngsutils) [27]. Uniquely mapped
sequencing reads were assigned to mm10 refGene genes using featureCounts (from subread) [28] with
the following parameters: “-s 2 –p –Q 10”. Quality control of sequencing and mapping results were
summarized using MultiQC [29]. The data were normalized using the TMM (trimmed mean of M
values) method. Differential expression analysis was performed using edgeR [30,31]. False discovery
rate (FDR) was computed from p-values using the Benjamini–Hochberg procedure.
2.8. Ingenuity® Pathway Analysis
Ingenuity® Pathway Analysis (IPA®) software (Qiagen, Germantown, MD, USA) was employed
to analyze relationships between genes that exhibited significant differential expression (FDR < 0.05)
as a result of binge METH treatment.
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3. Results
3.1. General Information from RNAseq
As seen in Table 1, we obtained identifiable sequences for around 10,000 genes in each brain region
and at each time point. STR appears to yield more genes that were significantly changed by METH
treatment than the PFC at both time points. The 2 h post-METH time point revealed the STR had
4483 genes and the PFC had 3118 genes that were significantly changed by METH. By the three-day
post-METH time point, only 714 genes reached a significant level of difference in expression and all
of those genes were in the STR. Of the 7601 genes significantly changed by METH at the 2 h time
point in the combined STR and PFC, 2483 genes were common to both regions, with 1255 of those
genes significantly upregulated in both STR and PFC and 1223 significantly downregulated in both
regions, considering all significant fold-changes (Figure 2a). The remaining five common genes are
listed in Table 2. Four genes (Plau, Itgb3, Tmem120a, Msto1) were significantly downregulated in PFC
while significantly upregulated in the STR and 1 gene (Grik5) was significantly upregulated in the PFC
while significantly downregulated in the STR. When fold-change values are restricted to those at least
two-fold (Figure 2b), the number of significantly changed genes common to both the STR and PFC is
reduced from 2483 to 779. Of those 779 genes, 435 are upregulated in both STR and PFC, while 342 are
downregulated. Plau and Grik2 remain present as genes significantly expressed in opposing directions
between the two brain regions. Note that the majority of the significant changes were less than two-fold
up or down across all comparisons.
Table 1. Number of genes with differential expression methamphetamine (METH) vs. saline, false
discovery rate (FDR) < 0.05 unpaired t-test. PFC: prefrontal cortex; STR: striatum; FC: fold change.
2 h Post METH 3 Day Post METH
Totals PFC Genes: 10,496 STR Genes: 10,839 PFC Genes: 9991 STR Genes: 10,612
Considering All FC’s with FDR < 0.05.
Totals PFC Genes: 3118 STR Genes: 4483 PFC Genes: 0 STR Genes: 714
Up Down Up Down Up Down Up Down
1537 1581 2435 2048 0 0 400 314
Considering FC’s > 2 or <−2 with FDR < 0.05.
Totals PFC Genes: 934 STR Genes: 1531 PFC Genes: 0 STR Genes: 78
Up Down Up Down Up Down Up Down
436 498 840 691 0 0 41 37
Table 2. Genes common to PFC and STR with opposite differential expression METH vs. saline, 2 h
time point, FDR <0.05 unpaired t-test.
Symbol Gene Name Fold Change PFC 2 h Fold Change STR 2 h
Grik5 Glutamate Ionotropic ReceptorKainate Type Subunit 5 3.39 −2.74
Plau Plasminogen Activator, Urokinase −2.25 4.04
Itgb3 Integrin Subunit Beta 3 −1.58 1.52
Tmem120a Transmembrane Protein 120A −1.30 1.40
Msto1 Misato Mitochondrial Distributionand Morphology Regulator 1 −1.31 1.29
Brain Sci. 2019, 9, 340 6 of 29
Brain Sci. 2018, 8, x FOR PEER REVIEW  5 of 26 
3. Results 
3.1. General Information from RNAseq 
As seen in Table 1, we obtained identifiable sequences for around 10,000 genes in each brain 
region and at each time point. STR appears to yield more genes that were significantly changed by 
METH treatment than the PFC at both time points. The 2 h post-METH time point revealed the STR 
had 4483 genes and the PFC had 3118 genes that were significantly changed by METH. By the three-
day post-METH time point, only 714 genes reached a significant level of difference in expression and 
all of those genes were in the STR. Of the 7601 genes significantly changed by METH at the 2 h time 
point in the combined STR and PFC, 2483 genes were common to both regions, with 1255 of those 
genes significantly upregulated in both STR and PFC and 1223 significantly downregulated in both 
regions, considering all significant fold-changes (Figure 2a). The remaining five common genes are 
listed in Table 2. Four genes (Plau, Itgb3, Tmem120a, Msto1) were significantly downregulated in PFC 
while significantly upregulated in the STR and 1 gene (Grik5) was significantly upregulated in the 
PFC while significantly downregulated in the STR. When fold-change values are restricted to those 
at least two-fold (Figure 2b), the number of significantly changed genes common to both the STR and 
PFC is reduced from 2483 to 779. Of those 779 genes, 435 are upregulated in both STR and PFC, while 
342 are downregulated. Plau and Grik2 remain present as genes significantly expressed in opposing 
directions between the two brain regions. Note that the majority of the significant changes were less 
than two-fold up or down across all comparisons. 
Table 1. Number of genes with differential expression methamphetamine (METH) vs. saline, false 
discovery rate (FDR) < 0.05 unpaired t-test. PFC: prefrontal cortex; STR: striatum; FC: fold change. 
 2 h Post METH 3 Day Post METH 
Totals PFC Genes: 10,496 STR Genes: 10,839 PFC Genes: 9991 STR Genes: 10,612 
Considering All FC’s with FDR < 0.05. 
Totals PFC Genes: 3118 STR Genes: 4483 PFC Genes: 0 STR Genes: 714 
 Up Down Up Down Up Down Up Down 
 1537 1581 2435 2048 0 0 400 314 
Considering FC’s > 2 or <−2 with FDR < 0.05. 
Totals PFC Genes: 934 STR Genes: 1531 PFC Genes: 0 STR Genes: 78 
 Up Down Up Down Up Down Up Down 
 436 498 840 691 0 0 41 37 
 
Brain Sci. 2018, 8, x FOR PEER REVIEW  6 of 26 
 
Figure 2. Distribution of significantly-changed genes FDR <0.05, 2 h post METH, in the STR and PFC. 
(a) all significantly changed genes; (b) significantly upregulated genes; (c) significantly 
downregulated genes. The relative number of significantly-changed genes are represented by the size 
of the circles. Genes significantly-changed in the prefrontal cortex are shown by blue circles while 
those from the striatum are shown by yellow circles. Genes shared by both regions are depicted by 
the overlapping area between the two circles in an olive color. Note that the striatum has the larger 
number of gene changes compared to the prefrontal cortex and that about 80% of the genes changed 
by METH in the PFC were also changed in the STR. 
Table 2. Genes common to PFC and STR with opposite differential expression METH vs. saline, 2 h 
time point, FDR <0.05 unpaired t-test. 
Symbol Gene Name 
Fold Change 
PFC 2 h 
Fold Change STR 2 
h 
Grik5 Glutamate Ionotropic Receptor Kainate Type Subunit 5 3.39 −2.74 
Plau Plasminogen Activator, Urokinase −2.25 4.04 
Itgb3 Integrin Subunit Beta 3 −1.58 1.52 
Tmem120a Transmembrane Protein 120A −1.30 1.40 
Msto1 Misato Mitochondrial Distribution and Morphology Regulator 1 −1.31 1.29 
There were 355 genes in the STR that were significantly changed at both the 2 h and 3 day time 
points. Of these 355 genes, 96 were upregulated at both time points, 70 were downregulated, 80 were 
up- then down-regulated and 109 were down- then upregulated. When restricted to fold changes >2 
or <−2, the number of genes fell to 6, 6, 5, and 4, respectively (Table 3). 
Table 3. Genes in STR with significant differential expression at both 2 h and 3 day time points, fold 
changes <−2 or >+2. 
Genes Upregulated at Both Time Points 
Symbol Gene Name Fold Change 2 h Fold Change 3 day 
Slc6a12 solute carrier family 6 member 12 16.60 2.75 
Csf1 colony stimulating factor 1 12.52 2.41 
Cd5 Cd5 molecule 3.40 2.29 
Fn1 fibronectin 1 3.14 2.65 
Adgrg5 adhesion G protein-coupled receptor G5 2.81 2.30 
LOC685157 similar to paired immunoglobin-like type 2 receptor beta 2.67 3.15 
Genes Downregulated at Both Time Points 
Symbol Gene Name Fold Change 2 h Fold Change 3 day 
Gpr12 G protein-coupled receptor 12 −5.74 −2.72 
Gba3 glucosidase, beta, acid 3 −5.40 −4.78 
Ripply3 ripply transcriptional repressor 3 −2.88 −2.13 
Sntb1 syntrophin, beta 1 −2.87 −2.00 
Tmem53 transmembrane protein 53 −2.49 −2.18 
Dscc1 DNA replication and sister chromatid cohesion 1 −2.44 −2.36 
Genes Upregulated at 2 h, Downregulated at 3 Days 
Symbol Gene Name Fold Change 2 h Fold Change 3 day 
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Avpr1a arginine vasopressin receptor 1A 2.71 −2.15 
Spata22 spermatogenesis associated 22 2.40 −4.78 
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Figure 2. Distribution of significantly-changed ge es F <0.05, 2 h post METH, in the STR and PFC.
(a) all significa changed genes; (b) significantly upregulated genes; (c) significantly downregulated
genes. The relative number of significantly-changed genes are represented by th size of the circles.
Genes significantly-changed in the prefrontal cortex are shown by blue circles while those from the
striatum are shown by yellow circles. Genes shared by both regions are depicted by the overlapping
area between the two circles in an olive color. Note that the striatum has the larger number of gene
changes compared to the prefrontal cortex and that about 80% of the genes changed by METH in the
PFC were also changed in the STR.
There were 355 genes in the STR that were significantly changed at both the 2 h and 3 day time
points. Of these 355 genes, 96 were upregula ed at both time points, 70 were downregulated, 80 were
up- then down-regulated and 109 were down- then upregulated. When restricted to fold changes >2
or <−2, the number of genes fell to 6, 6, 5, and 4, respectively (Table 3).
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Table 3. Genes in STR with significant differential expression at both 2 h and 3 day time points, fold
changes <−2 or >+2.
Genes Upregulated at Both Time Points
Symbol Gene Name Fold Change 2 h Fold Change 3 day
Slc6a12 solute carrier family 6 member 12 16.60 2.75
Csf1 colony stimulating factor 1 12.52 2.41
Cd5 Cd5 molecule 3.40 2.29
Fn1 fibronectin 1 3.14 2.65
Adgrg5 adhesion G protein-coupled receptor G5 2.81 2.30
LOC685157 similar to paired immunoglobin-like type 2 receptor beta 2.67 3.15
Genes Downregulated at Both Time Points
Symbol Gene Name Fold Change 2 h Fold Change 3 day
Gpr12 G protein-coupled receptor 12 −5.74 −2.72
Gba3 glucosidase, beta, acid 3 −5.40 −4.78
Ripply3 ripply transcriptional repressor 3 −2.88 −2.13
Sntb1 syntrophin, beta 1 −2.87 −2.00
Tmem53 transmembrane protein 53 −2.49 −2.18
Dscc1 DNA replication and sister chromatid cohesion 1 −2.44 −2.36
Genes Upregulated at 2 h, Downregulated at 3 Days
Symbol Gene Name Fold Change 2 h Fold Change 3 day
Hbegf heparin-binding EGF-like growth factor 17.55 −3.16
Bcl2 BCL2, apoptosis regulator 3.74 −2.14
Avpr1a arginine vasopressin receptor 1A 2.71 −2.15
Spata22 spermatogenesis associated 22 2.40 −4.78
Ccnd2 cyclin D2 2.31 −2.75
Genes Downregulated at 2 h, Upregulated at 3 Days
Symbol Gene Name Fold Change 2 h Fold Change 3 day
Islr immunoglobulin superfamily containing leucine-rich repeat −9.94 3.02
LOC689081 similar to cystatin E2 −6.14 2.23
Fndc1 fibronectin type III domain containing 1 −3.33 3.80
Hfe hemochromatosis −2.62 2.21
Table 4 lists the IPA® results of all genes with an FDR <0.05 in the STR or PFC at each time point
regardless of the degree of fold-change. At the 2 h time point, changes in gene expression induced
by binge METH in the STR and in the PFC share unfolded protein response as one of the top five
canonical pathways. Lipopolysaccharide and platelet-derived growth factor beta-beta (PDGF BB) are
common to both regions as the top five upstream regulators. STR and PFC share three of the five top
molecular and cellular functions (cell death and survival, cellular movement, cellular development).
However, at 3 days post-METH, the IPA® of the gene expression patterns dramatically changed in the
STR. At 2 h post-METH, the apparent emphasis of cellular functions was focused on more “macro”
processes such as cell development, movement, and death/survival. By 3 days post-METH, the cellular
function switched to more “micro” processes devoted to transcription and translation. Since there
were no longer any detectable gene expression changes in the PFC at the 3 day time point, no IPA® at
this time point could be performed.
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Table 4. Ingenuity® Pathway Analysis of significantly changed genes within each brain region and
time point.
Top Canonical
Pathways
Top Upstream
Regulators
Top Molecular and
Cellular Functions
STR 2 h post-METH,
FDR <0.05
NRF2-mediated
oxidative stress response Lipopolysaccharide Cell death and survival
Aryl hydrocarbon
receptor signaling PDGF BB Cellular movement
Unfolded protein
response Beta-estradiol Cellular development
Aldosterone signaling in
epithelial cells HSF1
Cellular growth and
proliferation
LXR/RXR activation TNF Cell morphology
PFC 2 h post-METH,
FDR <0.05
Aldosterone signaling in
epithelial cells Lipopolysaccharide Cellular movement
Unfolded protein
response IFNG Cell death and survival
Atherosclerosis signaling TGFB1 Protein synthesis
Granulocyte adhesion
and diapedesis IL1B
Cellular function and
maintenance
IL-10 signaling PDGF BB Cellular development
STR 3 day post-METH,
FDR <0.05
EIF2 signaling TCR RNA post-transcriptionalmodification
Regulation of eIF4 and
p70S6K signaling ERBB2 Protein synthesis
mTOR signaling DOT1L Cell death and survival
Type I diabetes mellitus
signaling EBI3 Gene expression
T helper cell
differentiation DRAP1
DNA replication,
recombination, and
repair
PFC 3 day post-METH,
FDR <0.05 N/A N/A N/A
Table 5 summarizes IPA® results using the RNAseq data for the 355 genes significantly expressed
in STR at both 2 h and 3 days post-binge METH with no restrictions on the fold-change. For the
subset of genes in the STR significantly upregulated at both time points, there is an emphasis on
pathways connected to gene and protein expression that influence cell morphology and cell-to-cell
interaction after binge METH. Pathways that reveal a consistent downregulation over time in the
STR after binge METH involve tryptophan degradation, nicotinamide adenine dinucleotide (NAD)
biosynthesis, and leukotriene biosynthesis. It appears that functions relating to DNA and cell replication
are slowed over time by this subset of genes. For the 80 genes initially upregulated significantly
at 2 h and then downregulated significantly at 3 days, regulation by NFkB may be involved as
three of the five top upstream regulators are IKBKE, RELB, and NFKB2. For the 109 genes initially
significantly downregulated at 2 h then upregulated at 3 days, NAD salvage was the top canonical
pathway identified.
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Table 5. Ingenuity® Pathway Analysis of significantly changed genes in STR at both 2 h and 3
days post-METH.
Top Canonical Pathways Top UpstreamRegulators
Top Molecular and
Cellular Functions
Upregulated at both 2 h
and 3 day post-METH
EIF2 signaling TCR RNA post-transcriptionalmodification
Regulation of eIF4 and p70S6K
signaling DOT1L Protein synthesis
mTOR signaling HSP90B1 Gene expression
Hepatic fibrosis/hepatic stellate cell
activation
miR-542-3p (miRNAs
w/seed GUGACAG) Cell morphology
Complement system ELAVL1 Cell-to-cell signaling andinteraction
Downregulated at both 2
h and 3 day post-METH
Tryptophan degradation to
2-amino-3-carboxymuconate
semialdehyde
BHLHA15 Cellular assembly andorganization
NAD biosynthesis II (from tryptophan) SOX11 DNA replication, recombination,and repair
Leukotriene biosynthesis ERBB2 Cell cycle
-Glutamyl cycle NAMPT Cellular growth and proliferation
Mismatch repair in eukaryotes CERS6 Cell morphology
Upregulated at 2 h and
downregulated at 3 day
-Linolenate biosynthesis II (animals) FAM103A1 Cellular assembly andorganization
Myc mediated apoptosis signaling IKBKE DNA replication, Recombinationand repair
Glycine biosynthesis I PIM1 Cell morphology
Pancreatic adenocarcinoma signaling RELB Cell death and survival
S-adenosyl-L-methionine biosynthesis NFKB2 Cell cycle
Downregulated at 2 h
and upregulated at 3 day
NAD salvage pathway II NDRG1 Lipid metabolism
IL-22 signaling COL18A1 Small molecule biochemistry
Natural killer cell signaling CDK4 Cell morphology
PI3K/AKT signaling PDLIM2 Cellular function and maintenance
Interferon signaling CLDN7 Cell death and survival
3.2. RNA Sequencing Data for the Cited Top 25 Genes Enriched in Microglia
Butovsky et al. [32] did an expansive study to create an RNA profile of microglia compared
to other monocyte lineage cells and cell lines as well as oligodendrocytes, astrocytes, and neurons.
Table 6 presents the current study’s data for the Butovsky et al. list of top 25 genes enriched in naïve
CD11b+ FRCLS+ adult mouse whole brain cells (microglia). Since these 25 genes represent a profile of
expression that may serve to define microglia vs. other cell types, we did not necessarily expect to
find that METH treatment would change the expression levels of these genes. However, 12 of these 25
genes were significantly changed by METH at the 2 h time point with four genes upregulated and eight
genes downregulated. Note that P2ry12 was significantly downregulated as reported in association
with microglial activation [33]. While we did not study any other cell type other than CD11b/c+ for this
study, these “microglia enriched” genes are very highly expressed compared to the average expression
level of all 10,839 detected genes. The average log2cpm (counts per million) for all genes was around
3.9 while the average log2cpm for the 24 detected genes listed in Table 6 was close to 9.
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Table 6. RNAseq data for top 25 genes enriched in microglia [32]. (U) = unique to microglia vs. oligodentrocyes, astrocytes, and neurons. Bold text = change in
expression FDR <0.05 METH vs. Saline treatment. ND = not detected. NS = not significant.
Symbol Gene Name STR Average log2cpmSaline (n = 6), METH (n = 8)
STR Fold Change, FDR 2 h
METH vs. Saline
PFC Average log2cpm
Saline (n = 4), METH (n = 5)
PFC Fold Change, FDR 2 h
METH vs. Saline
P2ry12 (U) purinergic receptor P2Y12 10.88, 9.77 −2.01, 5.0 × 10−5 10.93, 10.23 −1.57, 4.5 × 10−5
Tmem119 (U) transmembrane protein 119 11.24, 11.04 −1.19, 0.39 (NS) 11.28, 11.38 1.11, 0.72 (NS)
Fcrls (Fcrl2) (U) Fc receptor-like 2 10.04, 9.81 −1.08, 0.83 (NS) 10.51, 10.44 −1.11, 0.81 (NS)
Olfml3 (U) olfactomedin-like 3 1.18, −0.29 −2.78, 3.7 × 10−5 0.98, −0.08 −2.15, 0.04
Hexb (U) hexosaminidase subunit beta 12.68, 12.48 −1.14, 0.23 (NS) 12.77, 12.49 −1.20, 0.11 (NS)
Ctss cathepsin S 14.68, 15.04 1.30, 0.01 14.70, 15.05 1.29, 0.06 (NS)
C1qb complement C1q B chain 12.73, 13.23 1.44, 0.001 12.66, 13.36 1.66, 2.2 × 10−4
C1qa complement C1q A chain 12.57, 12.82 1.21, 0.11 (NS) 12.53, 12.89 1.31, 0.04
Csf1r colony stimulating factor 1 receptor 13.48, 13.62 1.10, 0.54 (NS) 13.42, 13.51 1.03, 0.85 (NS)
P2ry13 purinergic receptor P2Y13 9.27, 8.11 −2.04, 1.1 × 10−4 9.16, 8.53 −1.46, 0.01
Cx3cr1 C-X3-C motif chemokine receptor 1 12.27, 11.55 −1.50, 0.01 12.17, 11.73 −1.31, 0.11 (NS)
Gpr34 G protein-coupled receptor 34 11.39, 10.51 −1.72, 0.02 11.43, 10.54 −1.76, 0.004
C1qc complement C1q C chain 11.01, 11.30 1.20, 0.15 (NS) 10.85, 11.40 1.49, 0.11 (NS)
Mafb MAF bZIP transcription factor B 6.55, 7.31 2.06, 0.008 6.41, 6.74 1.27, 0.24 (NS)
Tgfbr1 (U) transforming growth factor, beta receptor 1 10.46, 10.39 −1.04, 0.80 (NS) 10.60, 10.50 −1.08, 0.62 (NS)
Fcgr1 Fc fragment of IgG receptor Ia 7.45, 7.15 −1.17, 0.33 (NS) 7.40, 7.23 −1.12, 0.50 (NS)
Entpd1 ectonucleoside triphosphatediphosphohydrolase 1 6.39, 5.52 −1.74, 3.0 × 10
−4 6.37, 5.86 −1.42, 0.02
Ltc4s leukotriene C4 synthase 8.11, 6.91 −2.14, 1.4 × 10−5 8.11, 7.35 −1.61, 8.5 × 10−4
Csf3r colony stimulating factor 3 receptor 8.30, 9.58 2.50, 1.2 × 10−7 8.24, 9.53 2.42, 8.6 × 10−9
Il10ra interleukin 10 receptor subunit alpha 8.35, 7.75 −1.52, 2.0 × 10−4 8.43, 8.07 −1.23, 0.06 (NS)
Egr1 early growth response 1 8.36, 8.81 1.91, 0.23 (NS) 8.30, 7.67 −1.39, 0,45 (NS)
Siglech sialic acid binding Ig like lectin H ND ND ND ND
Ccl2 C-C motif chemokine ligand 2 5.57, 6.34 2.15, 0.17 (NS) 5.66, 5.62 1.03, 0.97 (NS)
Lag3 lymphocyte activating 3 3.84, 3.80 1.01, 0.98 (NS) 3.83, 3.65 −1.16, 0.63 (NS)
Fos FBJ osteosarcoma oncogene 7.21, 7.31 1.09, 0.92 (NS) 8.45, 8.37 1.14, 0.86 (NS)
Average log2cpm
STR, Saline 10,839 Genes STR, METH 10,839 Genes PFC, Saline 10,496 Genes PFC, METH 10,496 Genes
3.93 3.91 4.13 4.14
STR, Saline Top 25 genes STR, METH Top 25 genes PFC, METH Top 25 genes PFC, METH Top 25 genes
9.34 9.16 9.38 9.25
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3.3. Comparison of RNA Sequencing Data to Gene Markers of Microglia vs. Macrophages
Table 7 contains the average log2cpm expression from our 2 h post-saline or post-METH STR
or PFC rat microglia of the top 25 genes designated by Hickman et al. [34] as being genes unique to
either microglia isolated via FACS from mouse whole brain or to peritoneal macrophages collected
by lavage. While 6 of the cited top 25 unique mouse microglial genes were not found in our set of
data, the remaining 19 were present with a log2cpm average of 7.5 to 8.5. Ten of the 25 unique mouse
macrophage genes were not present in our data on rats. The remaining 15 genes had an overall average
log2cpm around 2.0, a much lower expression than that of the microglial genes.
Table 7. Average log2cpm of genes unique to mouse brain microglia or peritoneal macrophages as per
Hickman et al. [34].
STR Average
Saline Microglial
log2cpm (n = 6)
STR Average
METH Microglial
log2cpm (n = 8)
PFC Average
Saline Microglial
log2cpm (n = 4)
PFC Average
METH Microglial
log2cpm (n = 5)
Mouse Microglial
Unique Genes 8.06 7.53 8.49 7.94
Mouse
Macrophage
Unique Genes
1.51 1.95 1.38 2.32
3.4. Comparison of METH-Induced RNAseq Gene Expression Changes to Reported M1 vs. M2
Polarization Markers
Microglia can be activated from a resting state to an activated state and subsequent polarization by
a variety of mediators released by a variety of insults. In broad terms, M1-polarization is characterized
as activated microglia which produce and release inflammatory mediators themselves, whereas,
M2-polarization is associated with activated microglia producing and releasing mediators which act in
a neuroprotective role. Table 8 compares RNAseq data from our 2 h post-METH STR and PFC to 47
genes cited in literature reviews as indicating M1 or M2 polarization of microglia [35–39]. Of these
47 genes, we found 12 genes were significantly changed by binge METH in the same direction as
reported in the literature (shaded in green). Five of these 10 genes (Cd32, Cd80, CXCL1, IL1a, IL1b)
were associated with M1 polarization while six of the 10 genes (Cd204, Dectin1, Gal3, Ifg1, Il1ra, Mrc1)
were associated with M2 polarization. Ptgs2 (COX2) was also upregulated and associated with M1 and
M2 polarization [35].
METH is known to upregulate COX2 expression at the RNA [40] and protein levels [17] in rodent
brains. One consequence of COX2 upregulation is the enhanced production of PG’s [41,42]. Therefore,
we examined the effects of binge-METH on the RNA expression levels of key molecules involved in PG
synthesis. As shown in Figure 3, genes whose proteins are involved in the release of arachidonic acid
(AA) from cell membranes and the subsequent synthesis of PG’s are upregulated 2 h after binge-METH
treatment. Additionally, there appears to be a diversion of AA to PG’s over the cysteinyl leukotrienes
(LT) via the corresponding downregulation or lack of detection of genes for the enzymes responsible for
LTC4, D4, and E4 synthesis. LTA4 could be directed instead to the production of LTB4 via upregulation
of Lta4h.
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Table 8. Literature-cited M1 or M2 microglial genes/proteins compared to RNAseq data. Green-font rows indicate significant change in expression that is directionally
in agreement with literature citations. Yellow-font rows indicate significantly changed RNAseq genes that are closely related to literature-cited genes. ND = not
detected. NS = not significant.
Symbol Gene Name M1/M2 Source BrainRegion
Average Log2
cpm Sal, METH
Fold
Change FDR
Ccl2 (MCP-1) C-C motif chemokine ligand 2 M1 Zhou
STR 5.57, 6.34 2.15 0.17 (NS)
PFC 5.66, 5.62 1.03 0.97 (NS)
Ccl5 (RANTES) C-C motif chemokine ligand 5 M1 Chhor
STR ND, ND ND
PFC ND, ND ND
Ccr7 C-C Motif Chemokine Receptor 7 M1 Barakat
STR ND, ND ND
PFC −4.59, −2.62 1.84 0.74 (NS)
Fcgr3a (Cd16) Fc fragment of IgG, low affinity IIIa, receptor M1 Barakat, Zhou
STR 8.12, 7.25 −1.78 8.5 × 10−8
PFC 8.01, 7.01 −1.97 1.5 × 10−9
Fcer2 (Cd23) Fc Fragment Of IgE Receptor II M1 Barakat
STR ND, ND ND
PFC ND, ND ND
Fcgr2a (Cd32) Fc fragment of IgG, low affinity IIa, receptor M1 Barakat, Zhou, Peng
STR 7.16, 7.79 1.58 9.6 × 10−7
PFC 7.25, 7.96 1.67 1.7 × 10−5
Cd40 (Tnfr) Cd40 molecule M1 Barakat
STR 6.08, 5.45 −1.46 0.13 (NS)
PFC 6.29, 5.30 −1.97 1.9 × 10−9
Cd80 Cd80 molecule M1 Barakat
STR 3.24, 3.62 1.34 0.049
PFC 3.30, 3.68 1.32 0.14 (NS)
Cd86 Cd86 molecule M1 Barakat, Zhou, Peng
STR 6.68, 6.47 −1.13 0.29 (NS)
PFC 6.54, 6.57 1.11 0.41 (NS)
Cxcl1 C-X-C motif chemokine ligand 1 M1 Chhor
STR −3.53, −0.28 6.3 0.01
PFC −2.30, 0.40 5.09 0.001
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Table 8. Cont.
Symbol Gene Name M1/M2 Source BrainRegion
Average Log2
cpm Sal, METH
Fold
Change FDR
Adgre1 (F4/80) adhesion G protein-coupled receptor E1 M1 Barakat
STR 10.32, 10.05 −1.2 0.06 (NS)
PFC 10.47, 10.35 −1.1 0.47 (NS)
Il1a interleukin 1 alpha M1 Chhor
STR 6.84, 7.93 3.98 0.001
PFC 6.76, 7.50 2.16 0.03
Il1b interleukin 1 beta M1 Barakat, Chhor
STR 3.83, 5.97 4.82 1.2 × 10−5
PFC 3.85, 6.28 5.57 7.6 × 10−13
Il2 Interleukin 2 M1 Chhor
STR ND, ND ND
PFC ND, ND ND
Il6 interleukin 6 M1 Barakat, Chhor,
Zhou
STR 3.05, 2.62 −1.26 0.35 (NS)
PFC 3.13, 3.33 1.17 0.58 (NS)
Il12 interleukin 12 M1 Barakat, Chhor
STR 5.04, 4.52 −1.36 0.045
PFC 4.89, 4.47 −1.25 0.32 (NS)
Ifng interferon gamma M1 Chhor
STR ND, ND ND
PFC ND, ND ND
Nos2 (iNos) nitric oxide synthase 2 M1 Barakat, Chhor
STR ND, ND ND
PFC ND, ND ND
Hla-d* (Mhc II) major histocompatibility class II M1 Barakat, Peng
STR ND, ND ND
PFC ND, ND ND
Tnf tumor necrosis factor M1 Barakat, Chhor,
Zhou
STR 1.19, 0.89 −1.26 0.49 (NS)
PFC 0.96, 0.46 −1.26 0.65 (NS)
Gene related to Tnf
from RNAseq Data
Tnfsf9 tumor necrosis factor superfamily member 9 STR 0.33, 4.29 19.53 5.7 × 10−11
PFC 0.23, 3.63 11.45 2.5 × 10−8
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Table 8. Cont.
Symbol Gene Name M1/M2 Source BrainRegion
Average Log2
cpm Sal, METH
Fold
Change FDR
Ptgs2(COX2) prostaglandin-endoperoxide synthase 2 M1/M2 Chhor
STR −4.73, −0.62 47.3 0.002
PFC ND, ND ND
Arg1 Arginase 1 M2 Cherry, Chhor
STR ND, ND ND
PFC ND, ND ND
Ccl2 (MCP-1) C-C motif chemokine ligand 2 M2 Chhor
STR 5.57, 6.34 2.15 0.17 (NS)
PFC 5.66, 5.62 1.03 0.97 (NS)
Ccr2 (MCP-1-R) C-C Motif Chemokine Receptor 2 M2 Chhor
STR ND, ND ND
PFC ND, ND ND
Cd163 CD163 molecule M2 Barakat, Cherry
STR ND, ND ND
PFC −2.16, 2.13 7.21 0.11 (NS)
Msr1 (Cd204) macrophage scavenger receptor 1 M2 Barakat
STR 1.38, 2.58 2.55 3.4 × 10−4
PFC 1.06, 3.01 4.18 2.6 × 10−6
Cd209 CD209 molecule M2 Barakat
STR ND, ND ND
PFC ND, ND ND
Cd36 CD36 molecule M2 Barakat
STR −2.79, −2.13 1.12 0.88 (NS)
PFC −2.15, −0.79 1.91 0.42 (NS)
Cd68 Cd68 molecule M2 Barakat
STR 6.83, 6.68 −1.11 0.38 (NS)
PFC 6.70, 6.49 −1.14 0.28 (NS)
Cxcr3 C-X-C motif chemokine receptor 3 M2 Chhor
STR 2.49, 1.61 −1.53 0.21 (NS)
PFC 2.79, 2.15 −1.54 0.01
Clec7a (Dectin 1) C-type lectin domain family 7, member A M2 Barakat, Cherry
STR 2.34, 2.59 1.38 0.35 (NS)
PFC 1.22, 2.75 3.02 0.006
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Table 8. Cont.
Symbol Gene Name M1/M2 Source BrainRegion
Average Log2
cpm Sal, METH
Fold
Change FDR
Retnlb (Fizz1) Resistin Like Beta M2 Barakat, Cherry,
Chhor
STR ND, ND ND
PFC ND, ND ND
Lgals3 (Gal-3) galectin 3 M2 Chhor
STR 0.79, 3.06 6.2 3.0 × 10−4
PFC 0.13, 2.49 6.7 6.8 × 10−4
Csf3 (G-CSF) Colony Stimulating Factor 3 M2 Chhor
STR ND, ND ND
PFC ND, ND ND
Csf2 (GM-CSF) Colony Stimulating Factor 2 M2 Chhor
STR ND, ND ND
PFC ND, ND ND
Gene related to Csf3
from RNAseq Data
Csf1 (M-CSF) Colony Stimulating Factor 1 STR 1.54, 4.91 12.52 7.6 × 10−9
PFC 1.71, 4.14 7.1 7.3 × 10−7
Igf1 insulin-like growth factor 1 M2 Chhor
STR 4.81, 5.26 1.41 0.01
PFC 4.87, 5.57 1.65 0.004
Il1rn (Il1ra) interleukin 1 receptor antagonist M2 Chhor
STR −0.40, 1.39 4.04 0.002
PFC −0.29, 1.19 3.43 0.4 (NS)
Genes related to Il1rn
from RNAseq Data
Il1rl1 (receptor for
IL33 with Il1RAP)
interleukin 1 receptor-like 1 STR 6.31, 5.82 −1.39 0.01
PFC 6.26, 5.87 −1.3 0.08 (NS)
Il1rap interleukin 1 receptor accessory protein STR 3.49, 3.94 1.36 0.004
PFC 3.29, 3.55 1.19 0.29 (NS)
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Table 8. Cont.
Symbol Gene Name M1/M2 Source BrainRegion
Average Log2
cpm Sal, METH
Fold
Change FDR
Il1r2 (IL1b decoy
receptor)
interleukin 1 receptor type 2 STR −1.75, 3.59 39.1 1.9 × 10−10
PFC −3.37, 4.48 131.46 2.0 × 10−10
Il4 Interleukin 4 M2 Barakat, Chhor
STR ND, ND ND
PFC ND, ND ND
Il4r Interleukin 4 Receptor M2 Chhor
STR 8.12, 8.41 1.25 0.21 (NS)
PFC 8.11, 8.39 1.23 0.16 (NS)
Il10 Interleukin10 M2 Barakat, Chhor
STR ND, ND ND
PFC ND, ND ND
Genes related to Il10
from RNAseq Data
Il10ra interleukin 10 receptor subunit alpha
STR 8.35, 7.75 −1.52 2.0 × 10−4
PFC 8.34, 8.07 −1.23 0.06 (NS)
Il10rb interleukin 10 receptor subunit beta
STR 7.98, 7.53 −1.34 6.0 × 10−4
PFC 7.94, 7.62 −1.22 0.04
Il13 Interleukin13 M2 Barakat
STR ND, ND ND
PFC ND, ND ND
Gene related to Il13
from RNAseq Data
Il13ra1 interleukin 13 receptor subunit alpha 1
STR 3.77, 4.01 1.18 0.19 (NS)
PFC 3.77, 4.48 1.6 1.7 × 10−3
Clec10a (Cd301) C-type lectin domain family 10, member A M2 Cherry
STR −0.89, −0.36 −1.19 0.75 (NS)
PFC 1.78, 3.67 4.08 0.08 (NS)
Mrc1 (Cd206) mannose receptor, C type 1 M2
Barakat Cherry,
Chorr, Zhou, Peng
STR −0.86, 0.66 2.72 0.009
PFC 0.83, 3.77 6.39 0.04
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Table 8. Cont.
Symbol Gene Name M1/M2 Source BrainRegion
Average Log2
cpm Sal, METH
Fold
Change FDR
Socs3 suppressor of cytokine signaling 3 M2 Chhor
STR 5.31, 5.49 1.04 0.91 (NS)
PFC 5.71, 6.13 1.34 0.29 (NS)
SphK1 Sphingosine Kinase 1 M2 Chhor
STR ND, ND ND
PFC ND, ND ND
SphK2 sphingosine kinase 2 M2 Chhor
STR 5.90, 6.02 1.1 0.37 (NS)
PFC 6.05, 6.23 1.14 0.30 (NS)
TGFb, subtypes
below M2 Barakat, Chhor
TGFb1 transforming growth factor, beta 1
STR 6.14, 6.14 −1.09 0.62 (NS)
PFC 6.34, 6.40 1 1.00 (NS)
TGFb2 transforming growth factor, beta 2
STR −1.15, −1.34 −1.14 0.80 (NS)
PFC ND, ND ND
TGFb3 transforming growth factor, beta 3
STR −0.63, −1.79 −1.27 0.72 (NS)
PFC −0.93, −1.46 −1.24 0.77 (NS)
Trem2 triggering receptor expressed on myeloid cells 2 M2 Cherry
STR 10.50, 9.06 −2.58 1.30 × 10−8
PFC 10.59, 8.88 −3.18 6.1 × 10−14
Chi3l3 (Ym1) chitinase 3 like 3 M2 Barakat, Cherry,
Chhor
STR ND, ND ND
PFC ND, ND ND
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Figure 3. Genes for prostaglandin (PG) and leukotrienes (LT) biosynthetic enzymes and LT receptors in 2 h 
post METH STR microglia. METH treatment appears to direct the release of arachidonic acid from cell 
membrane phospholipids toward synthesis of prostaglandins and leukotriene B4 which are known to have 
roles in inflammation. Downregulation or lack of detection of RNA for all leukotriene receptors [43] suggests 
that microglia are less responsive to leukotrienes post-binge METH. Changes in gene expression for enzymes 
and receptors are denoted by italic text and color: Black = not detected. Green = no significant change. Red = 
significant upregulation. Blue = significant downregulation. Gene expression data can be found in Table S1. 
Figure 3. Genes for prostaglandin (PG) and leukotrienes (LT) biosynthetic enzymes and LT receptors
in 2 h post METH STR microglia. METH treatment appears to direct the release of arachidonic acid
from cell membrane phospholipids toward synthesis of prostaglandins and leukotriene B4 which are
known to have roles in inflammation. Downregulation or lack of detection of RNA for all leukotriene
receptors [43] suggests that microglia are less responsive to leukotrienes post-binge METH. Changes in
gene expression for enzymes and receptors are denoted by italic text and color: Black = not detected.
Green = no significant change. Red = significant upregulation. Blue = significant downregulation.
Gene expression data can be found in Table S1.
Figure 4 illustrates that the genes that could yield proteins which enable the specific synthesis of
inflammatory mediator PGE2 from PGH2, along with two of the four receptors for PGE2, are upregulated.
This hints that exposure to binge METH could elicit an autocrine mechanism to positively feedback
onto an inflammatory pathway within CD11b/c+ cells. Since METH treatment does not change
Alox5 or Alox12 expression, generation of 5S- and 12S-HETE (Hydroxyeicosatetraenoic acid) may not
change, but their ability to possibly function in an autocrine fashion would likely be reduced since the
genes for the corresponding receptors, Oxer1 and Gpr31, are respectively not detected or significantly
downregulated. Alox15 is not detected; however, expression of the gene for a 15S-HETE receptor,
Ppard, is upregulated.
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Figure 4. Genes for biosynthetic enzymes and receptors for PG’s, TxA2, and HETE’s in 2 h post METH
STR microglia. METH treatment seems to direct the release of arachidonic acid from cell membrane
phospholipids particularly toward synthesis of PGE2 over any of the other possible cyclooxygenase- or
lipoxygenase-derived products. In addition, METH provides a means by which PGE2 can act in an
autocrine fashion with the concurrent upregulation of genes for PGE2 receptors EP2 and EP4. Changes
in gene expression are denoted by italic text and color: Black = not detected. Green = no significant
change. Red = significant upregulation. Blue = significant downregulation. Gene expression data can
be found in Table S2.
4. Discussion
Significant changes in gene expression were found in microglial cells of rat STR and PFC following
a binge METH dosing paradigm. These changes are detectable at 2 h after the last dose of METH,
with some changes persisting for up to 3 days. About one third of genes changed by binge METH
at 2 h after METH are shared by the STR and PFC. However, the microglia from the STR appear to
exhibit longer-lasting changes than microglia from the PFC given that the PFC had no significantly
changed genes at 3 days after METH. Since genes attributed as being unique to macrophages are either
not detected or are present only at very low levels, peripheral macrophages appear to have minimal
contribution to the number of CD11b/c+ cells collected from rat STR or PFC at 2 h post saline or METH.
Activation of microglia from the steady-state involves differential gene expression patterns that
direct the cell into one of at least two polarizations, the most common designations being M1 and
M2. At 2 h post-binge METH, microglia appear to be transitioning from a resting state to an M1
inflammatory-reactive state. Il1b is upregulated 2 h after the last dose of binge METH in both the STR
and PFC and emerges as a key marker of such activation. Moreover, P2ry12 was downregulated in
both brain regions at 2 h post-binge METH and is consistent with the finding that microglial activation
is associated with its downregulation [33]. These findings are in contrast to other known markers of M1
activation (Il6, Tnf, Ccl2, iNos, Nox) that were not changed after METH and suggest that microglia are
only in the early stages of responding to the insult of binge METH. Thus, this study provides insight
as to how soon microglia respond to binge METH and that IL1β is an early inflammatory mediator
produced by microglia after METH exposure. These findings add to a growing body of literature
that microglial activation can be further differentiated beyond M1 and M2 that depend on the type of
insult [44,45]. More specifically, microglial activation states also differ in rodent models of aging [34],
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retinal degeneration [38], ischemia [37,46], Alzheimer’s disease [47], Parkinson’s disease [48,49],
and binge alcohol consumption [39].
While Tnf RNA expression was not changed in response to binge METH treatment, there were
increases in the expression of a specific TNF superfamily member Tnfsf 9. Tnfsf 9 was upregulated
19.5-fold and 11.5-fold in the STR and PFC, respectively, at 2 h post-binge METH. TNFSF9 is also
known as CD137L or 4-1BBL, a transmembrane cytokine expressed on antigen presenting cells (APC),
including macrophages [50]. TNFSF9 interacts with its receptor, TNFRSF9 on activated T-cells, and
can generate a signaling cascade. Yeo et al. [51] demonstrated that interaction of TNFSF9 on BV2 and
N9 cells as well as on primary microglia resulted in responses typically associated with activation
of microglia to an inflammatory condition, including generation of reactive oxygen species (ROS).
Thus, binge METH may produce a specific upregulation in this one TNF superfamily member which
contributes to an M1 inflammatory activation state.
IL1β production after METH can be induced by LPS [52,53] that in turn, can increase the
release of PGE2 in a manner attenuated by COX inhibitor indomethacin [54], suggesting of a role for
prostaglandins and the arachidonic acid cascade. Furthermore, PGE2 acting through the EP2 receptor
was essential for pro-IL1βproduction induced by LPS in mouse bone-marrow derived macrophages [55].
Along these lines, Figures 3 and 4 illustrate that METH changes expression for a number of genes
involved in directing arachidonic acid metabolism toward PGE2 production that could be dependent
on LPS derived from a leaky gut. In fact, Persons et al. [56] showed that METH self-administration in
Fischer 344 rats resulted in lower expression of gut tight junction proteins claudin-1 and ZO-1 as well
as a morphological disorganization of these proteins in the colon. Additionally, human METH users
suffer from bowel ischemia which is associated with loss of gut integrity [57,58] that may lead to the
entry of LPS into the brain parenchyma as shown in rats following a METH-induced compromise of the
blood-brain-barrier [59]. Thus, high doses of METH may promote PGE2 production in brain microglia
that exacerbates LPS-induced IL1β production. The enhanced expression of Ptger2 suggested by our
current RNAseq data could further promote this cycle by allowing PGE2 to act in an autocrine fashion
to induce COX2 expression via EP2 receptor activation [60]. This feed-forward cycle involving LPS,
EP2, and COX2 is supported by the observation that EP2-deficient mice have reduced serum levels
of inflammatory mediators after the LPS challenge [61]. Moreover, activation of EP2 in cultures of
newborn Sprague-Dawley rat cortical microglia with PGE2 or butaprost upregulates mRNA’s encoding
COX2 and IL1β, as well as iNOS, and IL6 [62].
Il1r2 had a sharp increase in expression 2 h post-binge METH in both the STR (39-fold) and PFC
(131-fold). IL1R2 protein is a membrane-bound decoy receptor for IL1 expressed in mouse neutrophils
which under LPS-stimulation was increased to its cleaved soluble form by ADAM17 [63]. Johannson
et al. [64] found that Il1r2 RNA expression was enhanced in microglia isolated from adult mouse
brains exposed to Aβ peptide. The large increase in Il1r2 expression in microglia 2 h post-binge
METH indicates that microglia are similarly responsive to METH. Interestingly, Il1r2 expression was
significantly decreased in microglia from mouse brains exposed to Aβ peptide in EP2 knock-out mice
vs. wild type EP2 mice [64]. In addition, EP2-/- mice had enhanced microglial Aβ phagocytosis
characteristic of M2 anti-inflammatory microglia and a lack of Aβ-activated paracrine neurotoxicity [65].
It is possible that enhanced Ptger2 expression induced by binge METH treatment may serve to enhance
Il1r2 expression and suppress transition toward an M2 anti-inflammatory state in the early hours
after METH.
The production of the cysteinyl LT’s from AA may be diminished as illustrated by the gene
expression results in Figure 3. However, it is noted that Alox5 is present and Alox5ap is upregulated
which could still result in LTA4 synthesis. LTA4 is the precursor to not only the cysteinyl LT’s but also
to LTB4. The gene for the enzyme that converts LTA4 to LTB4, Lta4h, is significantly upregulated. LTB4
longevity could be enhanced via the downregulation of Ptgr1, the gene for prostaglandin reductase 1,
a key enzyme for inactivating LTB4 as an inflammatory mediator [66]. In models of LPS-induced septic
shock, Collin et al. [67] and Kwon et al. [68] demonstrated that inhibition of ALOX5 and antagonism
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LTB4 receptors, respectively, reduced multiple LPS-induced effects. Saiwai et al. [69] used a model of
spinal cord injury and reported that LTB4 receptor inhibition suppressed leukocyte infiltration and
attenuated the inflammatory reaction. Since no RNA for LTB4 receptors was detected in the RNAseq
data, the potential LTB4 production in microglia from METH-treated rats would not act in an autocrine
fashion, but most likely be released to stimulate LTB4 receptors on other cells. Thus, it appears that
LTB4 could be a potential contributor to METH-induced inflammation.
The IPA® results showed that there is an enhancement of the NRF2 (Nuclear factor erythroid
2-related factor 2) (NFE2L2)-mediated canonical pathway in the STR microglia at 2 h post METH.
METH is known to induce production of reactive oxygen species [13,70]. The NRF2-mediated pathway
is a cellular defense mechanism against oxidative stress (Figure 5). It is noteworthy that among the
elements which can activate this pathway are drugs, cytokines, prostaglandins, and bacterial infections.
NRF2 appears to be a key connection in the upregulation of Hsp’s 22 (Hspb8), 40 and 90, Stip1, Cct7, Nqo,
Gclc, Hmox-1, Ftl, Fth1, Sod1, Txnrd1, small Maf’s (Maff, Mafg, Mafk) as well as Nrf2 itself. Small MAF’s
and NRF2 dimerize to form transcriptional activators, suggesting another point of positive feedback in
STR after METH and further illustrates the different aspects of microglia activation. More specifically,
Hsp-22, Hsp-40 family member genes, and Hsp90 are significantly upregulated 2 h after METH (up to
37-fold) as are Stip1 (16-fold) and Fkbp5 (2-fold). HSP’s are critical to protein folding and maturation.
The protein product STIP1 is a co-chaperone for HSP90 and serves as a scaffold for the interaction
of HSP90 with HSP70. HSP90 ATPase activity is inhibited by PTGES3 by its binding to the closed
conformation of dimeric HSP90 and delaying release of a client protein [71]. Ptges3 is significantly
upregulated over 2-fold in both the STR and PFC 2 h post METH (Table S2). Thus, protein products of
Ptges3 may serve two roles by promoting the synthesis of PGE2 and by influencing the maturation and
folding of proteins.
CCT‘s, chaperonin containing TCP1 complexes, are also involved in the folding of proteins,
including actin and tubulin. Cct7, the gene for molecular chaperone subunit 7 of CCT, was significantly
upregulated in both the STR and PFC, 3.0- and 2.8-fold, respectively. LPS has been shown to stimulate
rearrangement of actin within primary cultures of peritoneal rat macrophages [72] and rat neonatal
microglia [73], which can be associated with changes in microglial morphology associated with
activation. Thus, upregulation of Cct7 may be associated with the folding of cytoskeletal proteins
linked to changes in morphology of microglia after activation.
Several genes upregulated by NFR2 are associated with detoxification of reactive species.
Nqo upregulation would result in expression of a protein that serves to detoxify reactive quinone species.
Dopamine quinone formation is induced by METH in dopaminergic neurons [74,75] and can activate
microglia [76]. Gclc upregulation can lead to enhanced expression of glutamyl cysteinyl ligase which is
the rate limiting enzyme in the synthesis of glutathione, a key molecule involved with the detoxification
of reactive species. Upregulation of Gclc and Sod1 could be associated with the microglial uptake of
glutamine. As shown in Figure 6, several genes for solute carriers involved with glutamine uptake are
significantly upregulated in microglia. It is known that METH causes the release of glutamate from
neurons [77,78] that is ordinarily taken up by astrocytes [79] and converted to glutamine [80], released
into the synaptic space and subsequently taken up by neurons where it is converted back glutamate.
The RNAseq data indicate that at 2 h post METH, the microglia may be primed to enhance their uptake
of glutamine and convert it ultimately to reduced glutathione via the 9-fold increase in Gclc (Figure 6).
Such a conversion along with the increase in Sod1 may be associated with a response by microglia to
detoxify reactive species but appear to be countered by the downregulation of genes for the enzymes
such as glutathione-S-transferases (GST), glutathione peroxidase 8 (GPX8), and catalase (CAT) needed
to complete the detoxification cycle. Consequently, the balance of effect could lead to the release and
accumulation of pro-oxidant species such as H2O2 [81,82] to produce the neurotoxicity to METH.
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Figure 6. Hypothesized pathway and consequences of glutamine uptake in 2 h post METH STR
microglia. Binge dose METH leads to neuronal release of glutamate. Glutamate is taken up by
astrocytes, converted to glutamine, and released to the extracellular space. Upregulation of genes for
several glutamine transporters suggests the enhanced uptake of glutamine by microglia. The potential
increased levels of glutamine would stoichiometrically be converted to glutamate and a monia [83].
The resulting enhanced levels of glutamate may be met by the enhanced expression of Gclc, the gene
for the first rate-limiting enzyme in glutathione synthesis, and enhanced expression of Slc7a11,
the gene for a cystine/glutamate transporter. This combination may drive the enhanced synthesis of
γ-glutamylcysteine and the reduced form of glutathione (GSH). The utility of GSH to participate in
detoxifying reactive species may be thwarted by the concurrent downregulation of genes for several
glutathione-S-transferases (GSTs). Enhanced expression of Sod1 via the IPA-predicted enhancement
NRF2 signaling may serve to partially reduce the amounts of METH-generated reactive oxygen species.
However, there is incomplete conversion of the resulting toxic hydrogen peroxide to water and alcohol
and accompanying generation of oxidized glutathione due to the downregulation of genes for catalase
(Cat) and glutathione peroxidase 8 (Gpx8), respectively. Other sources of toxic species resulting from
enhanced uptake of glutamine by microglia could be the enhanced presence/release of ammonia after the
conversion of glutamine to glutamate via the concurrent downregulation of glutamate dehydrogenase
1 (Glud1) as well as the enhanced export of glutamate via upregulated Slc7a11. Changes in gene
expression are denoted by text color and font for the gene symbol: Green = no significant change. Red,
bold = significant upregulation. Blue, bold = significant downregulation. Gene expression data can be
found in Table S4.
Several reviews point to the evolution from thinking of microglia as either simply M1 or M2
phenotypes to a spectrum of phenotypes or even sub-populations of cells specialized in their response
to a given stimulus [44,84,85]. One might envision a subset of microglia poised to respond to the insult
of toxic METH by locally generating COX2 expression and subsequently PGE2 production and release.
These cells could amplify their initial PGE2 response via autocrine signaling through enhanced EP2
expression, while also permitting activation of a separate subset of microglia poised to respond to
PGE2 via upregulated expression of EP4 receptors to enhance phagocytosis [86], suppress expression of
inflammatory mediators [87,88] and enhance expression of enzymes to detoxify reactive oxygen species
via NRF2 [89]. METH may serve to disrupt this coordinated effort by the incomplete detoxification of
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reactive species when Gclc and Sod1 are upregulated but Gpx8 and Cat are downregulated. Single-cell
RNAseq could be a useful tool to determine if such subpopulations of cells could exist.
There are only six genes upregulated >2-fold at both 2 h and 3 days in the STR after METH.
The gene for Betaine/GABA transporter 1, Slc6a12, is one of these genes (Table 3, Supplemental Table
S5). In a review by Kempson et al. 2014 [90], the role of this particular GABA transporter in the brain
is described as controversial since its expression levels relative to other GABA transporters are very
low. While expression levels of genes for GABA transporters in our RNAseq data from microglia
are modest, Scl6a12 is expressed at similar basal levels to the only other detected gene for a GABA
transporter, Slc6a1, which is not changed in the STR at either time point by METH. The role of potential
enhanced uptake of an inhibitory neurotransmitter by microglia for at least 3 days after METH has yet
to be explored.
Another gene that remains upregulated at 3 days after METH in the STR is Csf1 or macrophage
colony stimulating factor (Table 3, Table S6). CSF1 and activation of its receptor CSF1R, regulates the
survival, proliferation, and differentiation of macrophages and microglia during development [91].
The gene for CSF1R is highly expressed in all CD11b/c+ cells analyzed but its expression is not changed
by METH (Table S6). The alternative ligand for CSF1R, IL34, is significantly upregulated 3-fold at
3 days post METH in the STR (Table S6) and also can stimulate CSF1R. Thus, both ligands elicit a
pro-inflammatory phenotype in microglia [92] that persists for at least 3 days after METH.
5. Conclusions
The present RNA sequencing results indicate that CD11b/c+ cells isolated from rat STR and PFC
at 2 h post-binge METH appear to exhibit an RNA profile which indicates an overall inflammatory
activation state. It is noted that genes for some classical M1 markers were not expressed at higher levels
or even detected after exposure to METH. This may be due to the 2 h early time point chosen and/or to
the nature of how METH activates microglia. These cells appear to recover from the METH-induced
inflammatory profile rather quickly. By 3 days post-METH, there are no METH-induced transcriptional
changes in the PFC and the changes greater than 2-fold in the STR have dropped to only 78 genes.
It remains to be determined if the changes in RNA may be initiators of more prolonged and sustained
response by inflammatory proteins. A key pathway that appears to be involved in the inflammatory
nature of these cells in response to METH is the arachidonic acid metabolism cascade which favors the
production of PGE2. Consequently, PGE2 could be released from the microglia to activate EP receptors
on adjacent cells or to act potentially in an autocrine fashion as suggested by the METH-induced
upregulation of EP2 and EP4 receptors. Thus, the COX2-PGE2-EP2 cycle may enhance LPS-induced
IL1β production and a COX2-PGE2-EP4-NRF2-mediated cycle may drive the response to the oxidative
stress produced by METH.
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